Hypertension

9 trials 4 recruiting MedDRA PT
9 Registered trials
4 Recruiting
6 Unique sponsors
11 Unique IMPs
8 Commercial trials
Drug classes (ATC)
C Cardiology (ATC C) 1
— ATC code not specified 3
A Gastroenterology (ATC A) 3
H Endocrinology (ATC H) 1
M Musculoskeletal (ATC M) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 6 substances
Calcium channel blocker 1 substance
ACE inhibitor 1 substance
Statin 1 substance
SGLT2 inhibitor 1 substance
siRNA 1 substance
Phase III: 6 Phase II: 1 Phase I (Other): 1 Other: 1

Filter these 9 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 9 trials

Phase III

6 trials
  • Ablative Solutions Inc. Commercial
    ETHANOL, ANHYDROUS
    2024-512525-83-00 7 countries 2020 n=465
    Ended
  • Alnylam Pharmaceuticals Inc. Commercial
    ZILEBESIRAN
    2025-522960-34-00 17 countries 2026 n=4,000
    Recruiting
  • AstraZeneca AB Commercial
    BAXDROSTAT; DAPAGLIFLOZIN
    2023-506457-38-00 15 countries 2024 n=675
    Ended
  • AstraZeneca AB Commercial
    BAXDROSTAT; DAPAGLIFLOZIN
    2023-506460-14-00 15 countries 2025 n=1,134
    Recruiting
  • Mineralys Therapeutics Inc. Commercial
    LORUNDROSTAT; TETRACOSACTIDE
    2023-508670-28-00 8 countries 2024 n=370
    Ended
  • Uniwersytet Medyczny Im. Karola Marcinkowskiego W Poznaniu Academic
    ALLOPURINOL
    2024-517610-15-00 1 country 2024 n=1,116
    Recruiting

Phase II

1 trial
  • AstraZeneca AB Commercial
    BAXDROSTAT; DAPAGLIFLOZIN
    2025-522407-23-00 2 countries 2026 n=28
    Recruiting

Phase I (Other)

1 trial
  • Adamed Pharma S.A. Commercial
    IMP not specified
    2023-505153-41-00 1 country 2023 n=60
    Ended

Other

1 trial
  • Adamed Pharma S.A. Commercial
    AMLODIPINE; RAMIPRIL; RAMIPRIL, AMLODIPINE BESILATE, ROSUVASTATIN CALCIUM; ROSUVASTATIN CALCIUM
    2023-503822-38-00 1 country 2023 n=60
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AstraZeneca AB Commercial 3 Phase II, Phase III 2
Adamed Pharma S.A. Commercial 2 Other, Phase I (Other) 0
Ablative Solutions Inc. Commercial 1 Phase III 0
Alnylam Pharmaceuticals Inc. Commercial 1 Phase III 1
Mineralys Therapeutics Inc. Commercial 1 Phase III 0
Uniwersytet Medyczny Im. Karola Marcinkowskiego W Poznaniu Academic 1 Phase III 1
New trials by year
2020
1
2023
2
2024
3
2025
1
2026
2
← All indication landscapes